Skip navigation

IPPF Medical Bulletin

IPPF Medical Bulletin

IMAP is the International Medical Panel. This group of external experts in the sexual and reproductive health field collaborates with IPPF on a voluntary basis. They support IPPF's mission of ensuring sexual rights are recognised as human rights. Medical bulletins are produced quarterly with support from IPPF staff.

IPPF Medical Bulletin: Comparing injectable contraceptives

IMAP1 has developed this Statement because of recent shortages of DMPA in many countries. It provides, firstly, information and guidance to IPPF Member Associations which may need to procure NET-EN instead of DMPA and, secondly, offers guidance on how to enable clients to make a smooth transition from DMPA to NET-EN when medication shortages occur.

IPPF Medical Bulletin: Sexual rights and sexual health services

Sexual rights include the right to choose one’s sexual partner, to control one’s own body, to experience sexual pleasure, to not be abused or violated, to freely choose contraceptive methods, have access to safe and legal abortion, have access to information about prevention of sexually transmitted infections (STIs) and comprehensive sexuality education.

IPPF Medical Bulletin: Task sharing in sexual and reproductive health

This statement is intended to support the implementation of task sharing practices with the objective of increasing access to sexual and reproductive health essential services, particularly for those who are more vulnerable. It is primarily intended for use by IPPF Member Associations(MAs). It is also useful for all organisations, activists and researchers, policy and decision-makers who are working towards increasing universal access to services.


IPPF Medical Bulletin: the safety of third and fourth generation oral contraceptives

This statement is developed in response to recent public alarm in European countries, where women sued manufacturers for potential fatal blood clots (Venous Thromboembolism) as a result of using Meliane (Gestodene-containing oral contraceptive pill). The conclusions presented below do not apply to implants, IUS or other products containing the active components in third and fourth generation oral contraceptives.

IPPF Medical Bulletin: use of long acting reversible contraceptives by adolescents

This statement is developed to address the evidence on use of long acting reversible contraceptive (LARC) methods by adolescents. LARC methods include intrauterine devices (IUDs) and subdermal contraceptive implants which have durations of effective use between 3 and 10+ years, depending on the specific product selected by the client.